The American CEO of Swiss drugmaker Novartis on Friday warned that the United States' exit from the World Health Organization ...

Novartis chief executive says large pharma deals usually don't pay off. But the company remains interested in bolt-on ...

Ionis Pharmaceuticals (IONS) stock slips as Novartis (NVS) delays Phase 3 trial data for its cardiac therapy pelacarsen. Read more here.

The pharma major beat analysts’ expectations in the fourth quarter of 2024, despite looming competition for its top heart ...

Novartis was among the most prolific pharma dealmakers in 2024, a trend that it expects to continue with more bolt-on deals this year to set up for sustainable long-term growth.

Swiss drug-major Novartis AG reported Friday weak net earnings in its fourth quarter on the absence of prior year's significant gain ...

The Hospital for Special Surgery, a New York City-based musculoskeletal health organization that dates back to 1863, has received a $7.5 million gift that will support construction of a new orthopedic ...

By Nikhil Sharma (Reuters) -European shares reached a record high on Friday, led by technology and healthcare stocks, as ...

Reports Q4 revenue $13.2B vs. $11.4B last year. Vas Narasimhan, CEO of Novartis (NVS), said: “In our first full year as a pure-play innovative ...

Novartis said Friday that last year was one of its 'strongest' financial performances in its history following a multiyear ...

Despite the currency market anxiety, stocks pushed higher - with index futures adding to Thursday's Wall Street gains as the ...

Novartis’ (NOVN: VX) results show the firm humming along nicely in 2024, with sales driven by continued strong performance ...